Trasylol Safety Review Raises Questions About Role Of Observational Data
Executive Summary
FDA continues to grapple with the relative benefits of observational data and randomized controlled trials to evaluate drug safety
You may also be interested in...
Bayer Trasylol Being Pulled From Market After BART Trial Fails As Tourniquet
Though Bayer's anti-bleeding drug Trasylol has survived the assault of observational study data and the scrutiny of two joint advisory panels, preliminary data from a randomized controlled trial has finally knocked the drug from the market
Bayer Trasylol Being Pulled From Market After BART Trial Fails As Tourniquet
Though Bayer's anti-bleeding drug Trasylol has survived the assault of observational study data and the scrutiny of two joint advisory panels, preliminary data from a randomized controlled trial has finally knocked the drug from the market
Safety Trials In Trasylol ’s Future, But Design Could Prove Challenging
FDA and Bayer will begin discussions of post-marketing studies for the firm's Trasylol (aprotinin) due to suggestive but inconclusive observational data linking the drug to renal events and death